Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BioCryst Pharmaceuticals is a commercial-stage rare disease biotech focused on complement-mediated and metabolic disorders. The company's lead asset ORLADEYO (berotralstat) treats hereditary angioedema (HAE) and generated approximately $400M+ in 2025 sales, driving the transition to profitability. With a second commercial asset (RAPIVAB for influenza) and pipeline candidates in complement C3 disorders, BioCryst operates in high-margin orphan disease markets with limited competition.
BioCryst generates revenue through direct commercial sales of ORLADEYO in the US and EU for hereditary angioedema, a rare genetic disorder affecting approximately 1 in 50,000 people. The orphan drug designation provides 7-10 years of market exclusivity and premium pricing ($300K+ annual cost per patient). With 97% gross margins, profitability hinges on scaling patient enrollment beyond the current ~2,500-3,000 patients while managing SG&A costs. RAPIVAB provides seasonal influenza revenue through hospital channels. The company retains full commercial rights in major markets, avoiding royalty burdens that constrain many biotech peers.
ORLADEYO quarterly prescription trends and patient enrollment numbers (TRx data from Symphony Health)
Clinical trial readouts for pipeline assets, particularly BCX9930 (oral Factor D inhibitor) in complement-mediated diseases
Regulatory approvals in new geographies (Japan, additional EU markets) or label expansions
Cash runway updates and path to sustained profitability without additional dilution
Competitive dynamics in HAE market (Takeda's TAKHZYRO, CSL Behring's HAEGARDA, KalVista's oral Factor XIIa inhibitors)
Competitive threat from oral Factor XIIa inhibitors (KalVista's sebetralstat) that could offer superior efficacy or safety profiles in HAE, eroding ORLADEYO's market share
Pricing pressure from payers and potential inclusion in IRA drug price negotiations if revenue exceeds thresholds, though orphan drug exemptions may apply
Clinical trial execution risk for pipeline assets (BCX9930, galidesivir) with binary outcomes that could eliminate future growth drivers
Takeda's TAKHZYRO dominates injectable HAE prophylaxis market with strong efficacy data; ORLADEYO must differentiate on oral convenience despite potentially lower efficacy
CSL Behring and Pharming Group offer established C1-INH replacement therapies with decades of safety data
Ionis/Akcea's antisense therapies and emerging gene therapies could provide curative approaches that obsolete chronic prophylaxis
Negative equity position (negative book value) reflects accumulated losses; requires sustained revenue growth to rebuild shareholder equity
Cash burn of approximately $100M annually creates financing risk if ORLADEYO growth disappoints; current cash runway estimated 2-3 years at current burn rate
History of equity dilution (63.6% EPS growth despite 60.8% net income growth suggests share count reduction, but long-term dilution risk remains if profitability delayed)
low - Rare disease treatments are medically necessary and reimbursed by insurers/government payers regardless of economic conditions. HAE patients require prophylactic therapy to prevent life-threatening attacks, creating non-discretionary demand. However, healthcare budget pressures during recessions can slow payer approvals and increase prior authorization hurdles.
Rising rates negatively impact valuation multiples for pre-profitable biotechs as future cash flows are discounted more heavily. BioCryst carries minimal debt (negative D/E ratio suggests equity financing), so direct financing costs are not material. However, higher rates reduce appetite for speculative growth stocks and increase competition for capital, potentially limiting future financing flexibility if additional capital is needed before reaching sustained profitability.
Minimal direct credit exposure. Revenue is primarily from insured patients with reimbursement through commercial payers and government programs. The company maintains adequate liquidity (1.87x current ratio) and does not rely on credit markets for operations. However, tightening credit conditions could impact hospital purchasing of RAPIVAB and delay accounts receivable collections.
growth - Attracts speculative biotech investors focused on rare disease commercial execution and pipeline optionality. The 36% revenue growth and path to profitability appeal to growth-at-reasonable-price (GARP) investors, while negative cash flow and binary clinical risks deter value and income investors. Momentum traders respond to clinical catalysts and prescription data releases.
high - Small-cap biotech with binary clinical catalysts, limited analyst coverage, and significant short interest typical of the sector. Stock exhibits 40-50% annualized volatility based on recent performance (-22.7% 1-year return with wide intra-year swings). Clinical trial readouts and quarterly earnings can drive 20-30% single-day moves.
